BioSpace News Archive

Imcyse and Pfizer to collaborate to develop Imotope TM candidates to potentially treat Rheumatoid Arthritis Pfizer to lead clinical development and commercialization activities

Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines administered by tablet, today announced preliminary data from its Phase 1 study of VXA-CoV2-1 showing that its oral COVID-19 tablet vaccine candidate was generally well-tolerated, and immunogenic as measured by multiple markers of immune response to SARS-CoV-2 antigens.

ViaCyte, Inc., a clinical-stage regenerative medicine company, today announced that the first type 1 diabetes (T1D) patients have been implanted in a Phase 2 clinical study utilizing encapsulated delivery of cells.

R2 Technologies Inc. has received $10 million in funding from Huadong Medicine Company Limited as the third and final tranche of Huadong’s $30 million Series B equity investment.

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced that the National Cancer Institute’s (NCI) Phase 2 clinical study of PDS0101 for the treatment of advanced human papillomavirus (HPV)-associated cancers that have progressed or returned after treatment

Chengdu Kanghong Pharmaceutical Group, has received Special Protocol Assessments from the Food and Drug Administration for three new indications for its biologic drug conbercept.

AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that Dr. Scott T. Tagawa , M.D., M.S., FACP, a Professor of Medicine and Urology at Weill Cornell Medicine and an Attending Physician at New York-Presbyterian-Weill Cornell Medical Center

TMRW Life Sciences announces that it has launched the world’s first automated cryo specimen management solution for embryos and eggs used in in vitro fertilization.

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cfDNA testing, presented key results from its SMART study at the SMFM 41st Annual Pregnancy Meeting.

Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, announced that members of its leadership team will present at several upcoming investment events in February